Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales: Aogi, Kenjiro, Watanabe, Kenichi, Kitada, Masahiro, Sangai, Takafumi, Ohtani, Shoichiro, Aruga, Tomoyuki, Kawaguchi, Hidetoshi, Fujisawa, Tomomi, Maeda, Shigeto, Morimoto, Takashi, Sato, Nobuaki, Takao, Shintaro, Morita, Satoshi, Masuda, Norikazu, Toi, Masakazu, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606053/
https://www.ncbi.nlm.nih.gov/pubmed/36166110
http://dx.doi.org/10.1007/s10147-022-02237-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606053/
https://www.ncbi.nlm.nih.gov/pubmed/36166110
http://dx.doi.org/10.1007/s10147-022-02237-2

Ejemplares similares